Pharma Focus Asia

Nkarta Constructs New NK Cell Therapy Manufacturing Facility in South San Francisco

Introduction:

Nkarta, Inc. plans to construct new manufacturing facility. The facility will be home for company’s headquarters including administrative offices and laboratories for research & development activities.

Features:

The facility covering an area of 88,000 square foot facility will be used for supporting research and development activities and manufacturing of Nkarta's cell therapy pipeline in future.

The new state-of-the-art manufacturing center is custom designed to compliment and optimise the production of several off-the-shelf NK cell therapy investigational products. Moreover, the center will also produce materials for potential clinical trials.

The facility is expected to provide cost-effective treatment and meet the commercial production of cell therapies which can be made easily available for the cancer patients.

Recently, the construction of 2,700 square foot cGMP facility was completed in California and the construction of this new facility is expected to begin its operation by the end of 2023.

Specifications:

NameNkarta, Inc
TypeNew Construction
Year2023
magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024